- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|AL-3818 | AL3818 | catequentinib (proposed INN)|
|Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123 .
Note that anlotinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but has not (yet) been submitted to the World Health Organisation for ratification, and in fact a genuine INN request for 'catequentinib' has been submitted for this chemical structure to the WHO (in Proposed List 121).
|CAS Registry No.||1058156-90-3 (source: PubChem)|
|GtoPdb PubChem SID||340590231|
|Search Google for chemical match using the InChIKey||KSMZEXLVHXZPEF-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||KSMZEXLVHXZPEF|
|Search UniChem for chemical match using the InChIKey||KSMZEXLVHXZPEF-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||KSMZEXLVHXZPEF|